Current studies are investigating combination therapies including the addition of PI3K/Akt inhibitors to PARP inhibitors for HR deficient tumors, which may be important for BRCA2 deficient PCa tumors that exhibit PTEN co-loss [126]. Here, PIK3CA is linked to posterior cortical atrophy.